Diabetes CV Endpoints Suffer Renewed Criticism At Empagliflozin Meeting
Executive Summary
EMPA-REG data for Boehringer/Lilly's Jardiance highlight need to rethink diabetes trials' current three-point MACE endpoint that is heavily focused on atherosclerosis, FDA advisors say.
You may also be interested in...
At Liraglutide Panel Review, A Call For CV Studies To Look Beyond MACE
If cardiovascular studies are required for non-cardiac drugs, they should be focused on specific signals of heart-related concern that may not include ischemic events, advisory committee cardiologists say during review of Novo Nordisk’s Saxenda for obesity.
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.